Merus to Present at Upcoming Investor Conferences

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced upcoming presentations at two major investor conferences. CEO Bill Lundberg will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 9:40 a.m. ET and the Jefferies Global Healthcare Conference on June 4 at 3:10 p.m. ET. The presentations will be available via webcast on the company's Investors page, with recordings accessible for a limited time afterward.

News Market Reaction – MRUS

-7.87%

1 alert

-7.87% News Effect

On the day this news was published, MRUS declined 7.87%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the following investor conferences:

• William Blair 45th Annual Growth Stock Conference: Tuesday, June 3 at 8:40 a.m. CT/9:40 a.m. ET
  
• Jefferies Global Healthcare Conference: Wednesday, June 4 at 3:10 p.m. ET
  

The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.

About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, LinkedIn and Bluesky.

Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.

Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
s.spear@merus.nl

Kathleen Farren
Merus N.V.
Director IR/Corp Comms
617-230-4165
k.farren@merus.nl

FAQ

When is Merus (MRUS) presenting at the William Blair Conference in 2025?

Merus will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025, at 8:40 a.m. CT/9:40 a.m. ET.

What time is Merus (MRUS) presenting at the Jefferies Global Healthcare Conference?

Merus will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 3:10 p.m. ET.

Who will be presenting at the upcoming Merus (MRUS) investor conferences?

Bill Lundberg, M.D., President and Chief Executive Officer of Merus, will be presenting at the conferences.

Where can investors watch Merus (MRUS) conference presentations?

The presentations will be available via webcast on the Investors page of Merus's website, with archived versions available for a limited time after the events.